Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET.
Rhea-AI Summary
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET. Key presenters include William Collier (President and CEO), Dr. Michael Sofia (Chief Scientific Officer), Dr. Gaston Picchio (Chief Development Officer), and David Hastings (Chief Financial Officer). The chat will be accessible via a live webcast on Arbutus' website, with an archived replay available post-conference. The company focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ABUS
The recorded move for ABUS in the trading session of this news was -1.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARMINSTER, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 1:00 pm ET.
Arbutus Fireside Chat Presenters:
William Collier, President and CEO; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer.
A live webcast of the virtual fireside chat can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com or directly at Live Webcast. An archived replay of the webcast will be available on the Company’s website after the conference.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com
Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email: ir@arbutusbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.